摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

月桂酸钾 | 10124-65-9

中文名称
月桂酸钾
中文别名
——
英文名称
potassium laurate
英文别名
potassium dodecanoate;Kaliumlaurat;lauric acid potassium salt;potassium;dodecanoate
月桂酸钾化学式
CAS
10124-65-9
化学式
C12H23O2*K
mdl
——
分子量
238.412
InChiKey
HIDKSOTTZRMUML-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.136 g/cm3
  • LogP:
    1.190 (est)
  • 物理描述:
    Liquid

计算性质

  • 辛醇/水分配系数(LogP):
    -0.34
  • 重原子数:
    15
  • 可旋转键数:
    10
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    40.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2915900090
  • 储存条件:
    室温

SDS

SDS:95b226d248d6c55e0f7ffbf3c81a9dd1
查看

制备方法与用途

用途:用于制药工业。

反应信息

  • 作为反应物:
    描述:
    月桂酸钾氘氧化钾 作用下, 以 重水 为溶剂, 150.0 ℃ 、2.03 MPa 条件下, 反应 24.0h, 生成 deuteriated potassium laurate
    参考文献:
    名称:
    Nicoletta, Fiore Pasquale; Golemme, Attilio; Picci, Nevio, Gazzetta Chimica Italiana, 1996, vol. 126, # 5, p. 279 - 284
    摘要:
    DOI:
  • 作为产物:
    描述:
    月桂酸 在 potassium hydroxide 作用下, 生成 月桂酸钾
    参考文献:
    名称:
    Fatty Acid Potassium Had Beneficial Bactericidal Effects and Removed Staphylococcus aureus Biofilms while Exhibiting Reduced Cytotoxicity towards Mouse Fibroblasts and Human Keratinocytes
    摘要:
    伤口经常会被细菌感染或污染。植酸钾(C18:1K),一种脂肪酸钾,导致金黄色葡萄球菌和大肠杆菌数量在10分钟内减少了>4个对数菌落形成单位(CFU)/毫升,并在1分钟内将难辨梭菌数量减少了>2个对数CFU/毫升。C18:1K(去除比例:90.3%)在去除金黄色葡萄球菌生物膜方面明显比合成表面活性剂十二烷基硫酸钠(SLES)(74.8%,p < 0.01)和十二烷基硫酸钠(SLS)(78.0%,p < 0.05)更有效。在水溶性四唑盐(WST)测定中,C18:1K中的小鼠成纤维细胞(BALB/3T3克隆A31)(相对存活率与对照组比:102.8%)的存活率明显高于SLES(30.1%)或SLS(18.1%,p < 0.05)。在乳酸脱氢酶(LDH)泄漏测定中,C18:1K(相对泄漏与对照组比:108.9%)与从小鼠成纤维细胞泄漏的LDH比SLES或SLS(分别为720.6%和523.4%,p < 0.05)相关联。植酸钾对金黄色葡萄球菌、大肠杆菌、蜡样芽孢杆菌和难辨梭菌等各种物种表现出杀菌效果;去除的金黄色葡萄球菌生物膜材料显著多于SLES和SLS;并保持了成纤维细胞的生存能力;因此,它可能对伤口清洁和周围皮肤有用。
    DOI:
    10.3390/ijms20020312
  • 作为试剂:
    描述:
    4-碘代苯乙酮triethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)silane环己基丙二醇三(4-甲氧苯基)膦月桂酸钾copper(l) chloride 作用下, 以 甲苯 为溶剂, 反应 24.0h, 以66%的产率得到(E)-5-cyclohexyl-2-(4-iodophenyl)-4-(triethylsilyl)pent-4-en-2-ol
    参考文献:
    名称:
    Copper-catalyzed Silylative Allylation of Ketones and Aldehydes Employing Allenes and Silylboranes
    摘要:
    铜催化的酮与丙二烯和硅硼烷通过原位生成的β-硅基丙烯基铜中间体的硅醼化烯丙化反应已被开发。各种酮和丙二烯被选择性地转化为具有内消旋(E)-乙烯基硅烷基团的同烯丙基三级醇,产率良好至较高。醛也被用作反应中的亲电试剂。
    DOI:
    10.1246/cl.141018
点击查看最新优质反应信息

文献信息

  • GABA-LINKED ANTHRACYCLINE-LIPID CONJUGATES
    申请人:Swindell Charles S.
    公开号:US20120148595A1
    公开(公告)日:2012-06-14
    The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided.
    本发明涉及GABA-连接的蒽环类抗生素脂质共轭物,以及使用这些共轭物治疗癌症的方法。还提供了制备GABA-连接的蒽环类抗生素脂质共轭物的方法。
  • Benzimidazole Derivatives and Preparation Process and Pharmaceutical Uses Thereof
    申请人:WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD
    公开号:US20170022188A1
    公开(公告)日:2017-01-26
    The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include Ligustrazine and NO donor derivatives. The kind of the compounds can rapidly release Ligustrazine or No in vivo, so that they can produce effective synergetic effects with Azilsartan, to enhance the anti-hypertension effect, and reduce adverse effects, and the released Ligustrazine can produce ideal protection to patients' livers and kidneys, thereby filling blanks in the prior art
    这项发明属于药物化学技术领域,特别涉及苯并咪唑衍生物及其制备工艺和药用用途。苯并咪唑衍生物包括川芎素和NO供体衍生物。这些化合物可以在体内快速释放川芎素或NO,从而能够与阿利沙坦产生有效的协同作用,增强抗高血压效果,减少不良反应,释放的川芎素可以对患者的肝脏和肾脏产生理想的保护作用,从而填补了先前技术领域的空白。
  • [EN] SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION<br/>[FR] COMPOSÉS AROMATIQUES SUBSTITUÉS ET COMPOSITIONS PHARMACEUTIQUES POUR AUTO-RÉPARATION ET RÉGÉNÉRATION DE TISSU
    申请人:PROMETIC BIOSCIENCES INC
    公开号:WO2016074068A1
    公开(公告)日:2016-05-19
    Described herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, or combinations thereof, as well as uses thereof. Such uses include promoting tissue self-repair or tissue regeneration of an organ, stimulating the generation of tissue growth, modulating (e.g. increasing) the level of a tissue-repair marker, treating physical injury in an organ, tissue, or cell, promoting wound healing as well as anti-aging applications. Corresponding compositions, methods and uses are also described. Formula I wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n-CH3 or CH(OH)-(CH2)n-CH3 wherein n is 3 or 4; R1 is H, F of OH; R2 is H, F, OH, C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n-CH3 or CH(OH)-(CH2)n-CH3 wherein n is 3 or 4; R3 is H, F, OH, or CH2Ph; R4 is H, F or OH; Q is 1) (CH2),C(0)OH wherein m is 1 or 2 2) CH(CH3)C(0)OH, 3) C(CH3)2C(0)OH, 4) CH(F)-C(0)OH, 5) CF2-C(0)OH or 6) C(0)-C(0)OH.
    以下是公式I的化合物,或其药用可接受的盐,或它们的组合,以及它们的用途。这些用途包括促进器官的组织自我修复或组织再生,刺激组织生长的生成,调节(例如增加)组织修复标志物的水平,治疗器官、组织或细胞的物理损伤,促进伤口愈合以及抗衰老应用。还描述了相应的组合物、方法和用途。公式I中,A是C5烷基,C6烷基,C5烯基,C6烯基,C(0)-(CH2)n-CH3或CH(OH)-(CH2)n-CH3,其中n为3或4;R1是H,F或OH;R2是H,F,OH,C5烷基,C6烷基,C5烯基,C6烯基,C(0)-(CH2)n-CH3或CH(OH)-(CH2)n-CH3,其中n为3或4;R3是H,F,OH或CH2Ph;R4是H,F或OH;Q是1)(CH2)mC(0)OH,其中m为1或2 2)CH(CH3)C(0)OH,3)C(CH3)2C(0)OH,4)CH(F)-C(0)OH,5)CF2-C(0)OH或6)C(0)-C(0)OH。
  • BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
    申请人:SENOMYX, INC.
    公开号:US20160376263A1
    公开(公告)日:2016-12-29
    The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.
    本发明涵盖已知用于改变苦味感知的化合物和组合物,以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种:冷却剂;无活性药物成分;活性药用成分;食品添加剂或食品;调味剂或调味增强剂;食品或饮料产品;苦味化合物;甜味剂;苦味剂;酸味调味剂;咸味调味剂;鲜味调味剂;植物或动物产品;已知用于宠物护理产品中的化合物;已知用于个人护理产品中的化合物;已知用于家用产品中的化合物;制药制剂;局部制剂;大麻衍生或与大麻相关的产品;已知用于口腔护理产品中的化合物;饮料;香味、香水或除臭剂;已知用于消费品中的化合物;硅化合物;磨料;表面活性剂;发热剂;吸烟物品;脂肪、油脂或乳化剂;和/或益生菌或补充剂。
  • AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
    申请人:Kato Shiro
    公开号:US20100249399A1
    公开(公告)日:2010-09-30
    Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).]
    揭示了一种具有强烈亲和力的化合物,对5-羟色胺-4受体具有亲和力,可用作促进肠动力或改善消化道功能的药剂。具体地,揭示了一种由化学式(1)表示的化合物或其药学上可接受的盐。还具体揭示了一种含有由化学式(1)表示的化合物或其药学上可接受的盐的药物组合物。【在化学式(1)中,Ar代表由化学式(Ar-1)或化学式(Ar-2)表示的基团。】
查看更多